CRAB-RSS: development and validation of a single-center risk stratification model for carbapenem-resistant Acinetobacter baumannii in ICU patients based on mechanical ventilation, carbapenem exposure, and hospitalization duration
Frontiers in Cellular and Infection Microbiology · 2025
DOI: 10.3389/fcimb.2025.1659853 ↗Kurz gefasst
Validierungsstudie in der Zeitschrift Frontiers in Cellular and Infection Microbiology, 2025. Verfasst von Kun Li und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Laboratory Medicine, Suining Central Hospital, Suining, Sichuan, China. Hauptthemen laut MEDLINE: Acinetobacter baumannii, Carbapenems, Acinetobacter Infections, Respiration, Artificial. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Beatmung und Weaning, Intensivpflege
Abstract (Originalsprache)
Purpose
This study aimed to develop and validate the Carbapenem-Resistant Acinetobacter baumannii Risk Scoring System (CRAB-RSS), a novel predictive model designed to assess the risk of carbapenem-resistant A. baumannii (CRAB) infection in intensive care unit (ICU) patients.
Methods
A retrospective cohort analysis was performed on 412 patients (315 with CRAB and 97 with carbapenem-susceptible A.baumannii [CSAB]) from 2020 to 2024. Three independent risk factors were identified: mechanical ventilation (adjusted odds ratio [aOR] = 3.2, 95% confidence interval [CI]: 1.8–5.6), prior carbapenem exposure (≥48 hours; aOR = 1.89, 95% CI: 1.32–2.71), and hospitalization duration exceeding 14 days (aOR = 1.67, 95% CI: 1.25–2.23).
Results
The model demonstrated robust discriminative ability, with an area under the receiver operating characteristic curve (AUROC) of 0.887 in the derivation cohort and 0.918 in the validation cohort, along with satisfactory calibration (Brier score: 0.094 versus 0.088). Its performance was significantly superior to that of the Sequential Organ Failure Assessment (SOFA) score (ΔAUROC = +0.21).
Conclusions
CRAB-RSS is a quantitative risk stratification tool derived from a single-center cohort for CRAB infections in intensive care unit patients, demonstrating superior performance to SOFA in local validation. External multicenter validation is warranted before broad clinical implementation. Its innovative features include: (1) a fixed-weighting design (e.g., assigning a baseline score of 2 points for mechanical ventilation), and (2) reliance on only three readily obtainable clinical variables to complete the assessment. Decision curve analysis revealed that the application of CRAB-RSS could reduce unnecessary carbapenem use by 28%–42% across probability thresholds of 10%–30%, with a maximum reduction of 38% achieved at the 20% threshold.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Laboratory Medicine, Suining Central Hospital, Suining, Sichuan, China.
Zitieren
APA
Li, K., Wang, J., & Li, L. (2025). CRAB-RSS: development and validation of a single-center risk stratification model for carbapenem-resistant Acinetobacter baumannii in ICU patients based on mechanical ventilation, carbapenem exposure, and hospitalization duration. Frontiers in Cellular and Infection Microbiology. https://doi.org/10.3389/fcimb.2025.1659853
Vancouver
Li K, Wang J, Li L. CRAB-RSS: development and validation of a single-center risk stratification model for carbapenem-resistant Acinetobacter baumannii in ICU patients based on mechanical ventilation, carbapenem exposure, and hospitalization duration. Frontiers in Cellular and Infection Microbiology. 2025. doi:10.3389/fcimb.2025.1659853
BibTeX
@article{Li2025,
author = {Li, Kun and Wang, Jie and Li, Long},
title = {CRAB-RSS: development and validation of a single-center risk stratification model for carbapenem-resistant Acinetobacter baumannii in ICU patients based on mechanical ventilation, carbapenem exposure, and hospitalization duration},
journal = {Frontiers in Cellular and Infection Microbiology},
year = {2025},
doi = {10.3389/fcimb.2025.1659853}
}
EUVIMED